BR9812785A - "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase" - Google Patents

"imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase"

Info

Publication number
BR9812785A
BR9812785A BR9812785-3A BR9812785A BR9812785A BR 9812785 A BR9812785 A BR 9812785A BR 9812785 A BR9812785 A BR 9812785A BR 9812785 A BR9812785 A BR 9812785A
Authority
BR
Brazil
Prior art keywords
phenyl
imidazotriazinones
phosphodiesterase inhibitors
substituted
substituted imidazotriazinones
Prior art date
Application number
BR9812785-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Ulrich Niewoehner
Mazen Es-Sayed
Helmut Haning
Thomas Schenke
Karl-Heinz Schlemmer
Joerg Keldenich
Erwin Bischoff
Elisabeth Perzborn
Klaus Dembowsky
Peter Serno
Marc Nowakowsky
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9812785A publication Critical patent/BR9812785A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR9812785-3A 1997-11-12 1998-10-31 "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase" BR9812785A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone
PCT/EP1998/006910 WO1999024433A1 (de) 1997-11-12 1998-10-31 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren

Publications (1)

Publication Number Publication Date
BR9812785A true BR9812785A (pt) 2000-10-10

Family

ID=27217917

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9812785-3A BR9812785A (pt) 1997-11-12 1998-10-31 "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase"
BRPI9816155-5A BR9816155B1 (pt) 1997-11-12 1998-10-31 imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase, bem como medicamento e uso farmacêutico compreendendo as mesmas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9816155-5A BR9816155B1 (pt) 1997-11-12 1998-10-31 imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase, bem como medicamento e uso farmacêutico compreendendo as mesmas.

Country Status (43)

Country Link
US (9) US6362178B1 (cg-RX-API-DMAC7.html)
EP (3) EP1174431B1 (cg-RX-API-DMAC7.html)
JP (2) JP3356428B2 (cg-RX-API-DMAC7.html)
KR (2) KR100548120B1 (cg-RX-API-DMAC7.html)
CN (2) CN100430396C (cg-RX-API-DMAC7.html)
AR (2) AR013759A1 (cg-RX-API-DMAC7.html)
AT (1) ATE213246T1 (cg-RX-API-DMAC7.html)
AU (1) AU738675B2 (cg-RX-API-DMAC7.html)
BG (1) BG65257B1 (cg-RX-API-DMAC7.html)
BR (2) BR9812785A (cg-RX-API-DMAC7.html)
CA (2) CA2309332C (cg-RX-API-DMAC7.html)
CH (1) CH693954A5 (cg-RX-API-DMAC7.html)
CO (1) CO4980861A1 (cg-RX-API-DMAC7.html)
CU (1) CU23063A3 (cg-RX-API-DMAC7.html)
CY (1) CY1112949T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301911B6 (cg-RX-API-DMAC7.html)
DE (3) DE59803108D1 (cg-RX-API-DMAC7.html)
DK (3) DK1049695T3 (cg-RX-API-DMAC7.html)
EE (1) EE04781B1 (cg-RX-API-DMAC7.html)
ES (3) ES2386420T3 (cg-RX-API-DMAC7.html)
FI (1) FI113772B (cg-RX-API-DMAC7.html)
GB (1) GB2346877B (cg-RX-API-DMAC7.html)
HN (1) HN1998000175A (cg-RX-API-DMAC7.html)
HR (2) HRP20020585B1 (cg-RX-API-DMAC7.html)
HU (3) HU230154B1 (cg-RX-API-DMAC7.html)
ID (1) ID25871A (cg-RX-API-DMAC7.html)
IL (3) IL135462A0 (cg-RX-API-DMAC7.html)
IN (1) IN188419B (cg-RX-API-DMAC7.html)
LU (1) LU90561B1 (cg-RX-API-DMAC7.html)
MY (1) MY138535A (cg-RX-API-DMAC7.html)
NO (2) NO314940B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504436A (cg-RX-API-DMAC7.html)
PE (1) PE131799A1 (cg-RX-API-DMAC7.html)
PL (2) PL194801B1 (cg-RX-API-DMAC7.html)
PT (2) PT1049695E (cg-RX-API-DMAC7.html)
SE (1) SE522809C2 (cg-RX-API-DMAC7.html)
SI (2) SI1049695T1 (cg-RX-API-DMAC7.html)
SK (1) SK287161B6 (cg-RX-API-DMAC7.html)
TR (1) TR200001338T2 (cg-RX-API-DMAC7.html)
TW (2) TWI229081B (cg-RX-API-DMAC7.html)
UA (1) UA46166C2 (cg-RX-API-DMAC7.html)
UY (2) UY25246A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999024433A1 (cg-RX-API-DMAC7.html)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
DK1049695T3 (da) * 1997-11-12 2002-05-13 Bayer Ag 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
IL139454A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20050020547A1 (en) * 1999-11-08 2005-01-27 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
DE50008549D1 (de) * 1999-12-24 2004-12-09 Bayer Healthcare Ag Triazolotriazinone und ihre verwendung
JP2003519153A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト イソオキサゾロピリミジノン類及びその使用
WO2001047928A2 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinone und ihre verwendung
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CZ20031194A3 (cs) * 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
US6683080B2 (en) 2001-02-02 2004-01-27 Pfizer Inc. Treatment of diabetes mellitus
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
MXPA04001891A (es) 2001-08-28 2004-06-15 Schering Corp Inhibidores policiclicos de guanina fosfodiesterasa v.
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
BRPI0207215B8 (pt) * 2001-12-13 2022-11-01 Daiichi Suntory Biomedical Res Limited Derivados de pirazolopirimidinona tendo ação de inibição de pde7
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
PL374198A1 (en) * 2002-05-23 2005-10-03 Pfizer Inc. Novel combination
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2006522127A (ja) * 2003-04-01 2006-09-28 スミスクライン ビーチャム コーポレーション イミダゾトリアジン化合物
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
CN1791429A (zh) 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
PE20050985A1 (es) * 2003-11-21 2005-11-26 Schering Corp Formulaciones de inhibidores de la fosfodiesterasa v
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7449462B2 (en) 2004-01-22 2008-11-11 Pfizer, Inc. Triazole derivatives which inhibit vasopressin antagonistic activity
ATE417849T1 (de) * 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
CA2576961A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
EA200701752A1 (ru) * 2005-02-18 2008-04-28 Сурфейс Логикс Инк. Способ получения усовершенствованных фармакокинетических соединений, включающих функциональные остатки или группы, и фармацевтические композиции, содержащие эти соединения
UA90502C2 (ru) * 2005-02-18 2010-05-11 Сьёрфейс Лоджикс, Инк. Имидазотриазиноновые соединения и фармацевтическая композиция, которая их содержит
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
MX2007012711A (es) 2005-04-19 2008-01-11 Nycomed Gmbh Roflumilast para el tratamiento de hipertension pulmonar.
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
BRPI0616633A2 (pt) 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PE20080109A1 (es) * 2006-02-17 2008-04-01 Wyeth Corp N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
EP2596785A1 (en) * 2006-03-17 2013-05-29 Johns Hopkins University School of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007264030B2 (en) 2006-06-27 2012-04-05 Sandoz Ag New method for salt preparation
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
CN101528042A (zh) * 2006-08-24 2009-09-09 表面线段公司 药代动力学改进的化合物
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
EP2114147B9 (en) 2007-02-12 2013-04-10 DMI Biosciences, Inc. Reducing side effects of tramadol
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
CN101657101B (zh) * 2007-02-12 2013-12-11 Dmi生物科学公司 并存早泄和勃起功能障碍的治疗
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
WO2009030095A1 (fr) * 2007-09-06 2009-03-12 Topharman Shanghai Co., Ltd. Procédé de préparation de vardénafil et de ses intermédiaires
ES2388371T3 (es) 2007-12-28 2012-10-15 Topharman Shanghai Co., Ltd. N-{1-[3-(2-etoxi-5-(4-etilpiperazinil)bencenosulfonil)-4,5-dihidro-5-oxo-1,2,4-triazin-6-il]etil}-butiramida, método de preparación y uso
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
CA2770471A1 (en) 2009-08-07 2011-02-10 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
KR101766931B1 (ko) 2009-11-27 2017-08-09 아드베리오 파마 게엠베하 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
TWI541244B (zh) 2010-09-20 2016-07-11 福倫製藥股份有限公司 咪唑三酮化合物
CA2809675A1 (en) 2010-09-23 2012-03-29 Shuang Chen Monohydrate of an azaadamantane derivative
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ2011767A3 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
AU2013213603B2 (en) 2012-01-26 2017-02-02 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
JP5941558B2 (ja) 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
ES2903151T3 (es) 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
EA201500852A1 (ru) 2013-02-21 2016-02-29 Адверио Фарма Гмбх Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
DK3377495T3 (da) * 2015-11-16 2022-05-09 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018112258A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
WO2018215433A1 (en) 2017-05-22 2018-11-29 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
AU2018386444A1 (en) 2017-12-20 2020-07-23 Klaria Pharma Holding Ab Film formulation comprising vardenafil, method for its preparation, and use thereof
CA3090277A1 (en) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
EP3807897A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CA3103716A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CN112996512B (zh) 2018-08-31 2025-01-03 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
KR20210096626A (ko) * 2018-11-28 2021-08-05 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
WO2020184670A1 (ja) 2019-03-13 2020-09-17 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
MX2023006911A (es) * 2020-12-11 2023-06-26 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de androgenos y de la fosfodiesterasa.
CA3214215A1 (en) * 2021-04-21 2022-10-27 Yunlong Song Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
WO2023052407A1 (en) 2021-09-29 2023-04-06 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
KR20240154529A (ko) 2022-03-02 2024-10-25 토파두르 파마 아게 국소 조성물 및 이들의 용도
TW202428579A (zh) * 2022-10-19 2024-07-16 大陸商長春金賽藥業有限責任公司 Ｎｋ３ｒ拮抗劑的晶型及其製備方法和用途
WO2024173675A1 (en) 2023-02-16 2024-08-22 University Of Rochester Improving glymphatic-lymphatic efflux

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (cg-RX-API-DMAC7.html) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
EP0054132B1 (de) 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
JPH05506011A (ja) * 1990-04-11 1993-09-02 ジ・アップジョン・カンパニー 流動床コーティングによるイブプロフェンの味覚マスキング
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
CA2148260A1 (en) 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
DK1049695T3 (da) * 1997-11-12 2002-05-13 Bayer Ag 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
WO2001047928A2 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinone und ihre verwendung
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Also Published As

Publication number Publication date
SI1049695T1 (en) 2002-06-30
UY25671A1 (es) 2000-03-31
KR100548120B1 (ko) 2006-02-02
HN1998000175A (es) 1999-01-08
JP3356428B2 (ja) 2002-12-16
SE0001745L (sv) 2000-05-11
US7704999B2 (en) 2010-04-27
FI20001086L (fi) 2000-05-09
ATE213246T1 (de) 2002-02-15
ES2386420T3 (es) 2012-08-20
JP4388729B2 (ja) 2009-12-24
CN1123573C (zh) 2003-10-08
DK200000766A (da) 2000-05-09
PL201336B1 (pl) 2009-03-31
DE19881732C1 (de) 2002-01-31
ID25871A (id) 2000-11-09
PE131799A1 (es) 1999-12-30
ES2172945T3 (es) 2002-10-01
ES2194567B1 (es) 2005-03-01
EE200000291A (et) 2001-06-15
IL135462A0 (en) 2001-05-20
CA2309332C (en) 2002-12-03
NO20002444L (no) 2000-05-11
MY138535A (en) 2009-06-30
PL194801B1 (pl) 2007-07-31
CA2395558A1 (en) 1999-05-20
EP2295436A1 (de) 2011-03-16
AR035972A2 (es) 2004-07-28
AR013759A1 (es) 2001-01-10
KR100430355B1 (ko) 2004-05-04
HU227841B1 (en) 2012-05-02
UY25246A1 (es) 2001-08-27
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
NO20021714L (no) 2000-05-11
SI1174431T1 (sl) 2012-09-28
US6566360B1 (en) 2003-05-20
NO314940B1 (no) 2003-06-16
CY1112949T1 (el) 2016-04-13
CO4980861A1 (es) 2000-11-27
PT1174431E (pt) 2012-07-24
CZ301911B6 (cs) 2010-07-28
DK176852B1 (en) 2009-12-14
EP1174431A3 (de) 2002-01-30
GB0010974D0 (en) 2000-06-28
AU1558799A (en) 1999-05-31
DK1049695T3 (da) 2002-05-13
LU90561B1 (de) 2000-12-01
BR9816155B1 (pt) 2010-07-27
CU23063A3 (es) 2005-07-19
CA2309332A1 (en) 1999-05-20
DE59803108D1 (de) 2002-03-21
HRP20020585A2 (en) 2005-10-31
EP1174431A2 (de) 2002-01-23
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
AU738675B2 (en) 2001-09-20
HK1031730A1 (en) 2001-06-22
UA46166C2 (uk) 2002-05-15
CN100430396C (zh) 2008-11-05
BG65257B1 (bg) 2007-10-31
CH693954A5 (de) 2004-05-14
EP1049695B1 (de) 2002-02-13
TWI229081B (en) 2005-03-11
NO20021714D0 (no) 2002-04-11
EE04781B1 (et) 2007-02-15
PT1049695E (pt) 2002-07-31
US20100016323A1 (en) 2010-01-21
HU228196B1 (en) 2013-01-28
CN1508137A (zh) 2004-06-30
SK7092000A3 (en) 2001-03-12
US20060189615A1 (en) 2006-08-24
ES2194567A1 (es) 2003-11-16
IN188419B (cg-RX-API-DMAC7.html) 2002-09-21
HRP20000292B1 (hr) 2008-09-30
US6362178B1 (en) 2002-03-26
SK287161B6 (sk) 2010-02-08
JP2001522851A (ja) 2001-11-20
GB2346877A (en) 2000-08-23
JP2002348290A (ja) 2002-12-04
US6890922B2 (en) 2005-05-10
US7122540B2 (en) 2006-10-17
DE19881732D2 (de) 2000-08-24
HU230154B1 (hu) 2015-09-28
HUP0100394A2 (hu) 2001-09-28
HRP20020585B1 (hr) 2013-02-28
EP1049695A1 (de) 2000-11-08
US20110009367A1 (en) 2011-01-13
DK1174431T3 (da) 2012-08-20
WO1999024433A1 (de) 1999-05-20
BG104406A (en) 2001-08-31
NO20002444D0 (no) 2000-05-11
US20080113972A1 (en) 2008-05-15
KR20010031944A (ko) 2001-04-16
US20040067945A1 (en) 2004-04-08
HK1067124A1 (zh) 2005-04-01
PL340400A1 (en) 2001-01-29
US7696206B2 (en) 2010-04-13
CZ20001759A3 (cs) 2000-10-11
CA2395558C (en) 2007-07-17
US7314871B2 (en) 2008-01-01
US20050070541A1 (en) 2005-03-31
FI113772B (fi) 2004-06-15
GB2346877B (en) 2001-12-05
EP1174431B1 (de) 2012-05-30
TR200001338T2 (tr) 2000-08-21
IL163475A (en) 2015-11-30
CN1278822A (zh) 2001-01-03
TW513431B (en) 2002-12-11
SE522809C2 (sv) 2004-03-09
HRP20000292A2 (en) 2001-04-30
IL135462A (en) 2006-04-10
HUP0100394A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
BR9812785A (pt) "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase"
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
BR0208594A (pt) Métodos de inibição de corrosão em sistemas aquosos e de preparação de uma composição compreendendo adutos de ácido fosfinossuccìnico mono, bis e oligoméricos, e, composição aquosa
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
BR9810857B1 (pt) composto quìmico, processos para a preparação do mesmo, para a preparação de um composto organoboro-alumìnio cocataliticamenteativo, e para a preparação de uma poliolefina na presença de um sistema catalisador, composto organoboro-alumìnio, sistema catalisador, e, uso do mesmo.
AR006108A1 (es) Pirimido[5,4-d]pirimidinas, sus sales fisiologicamente compatibles, un procedimiento para su preparacion, su empleo para la preparacion de composiciones farmaceuticas, y las composiciones farmaceuticas que las contienen
BRPI0408492A (pt) processo para preparar ditioésteres
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
BR9909624A (pt) Linhagens de células do sistema nervoso periférico (pns) e processos de utilização para as memas
BR0007864A (pt) Composto, e, uso de um composto
DK1334116T3 (da) En fremgangsmåde til fremstilling af polyphenoliske adhæsive proteiner
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ATE89561T1 (de) 3,4-disubstituierte-2-azetidinon-derivate und verfahren zu ihrer herstellung.
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
CO5150166A1 (es) (s)-10, 11-dihidro-3[2-(5,6,7,8-tetrahidro-1,8-naftiridin -2-il)-etoxi]-5h-dibenzo [a,d] cicloheptano-10-acido acetico
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
BR0112122A (pt) Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto
BRPI0416821A (pt) processo para a preparação de pirazolo[1,5-a]-1,3,5-triazinas e seus intermediários
UA84020C2 (ru) Ингибитор проникновения вируса вил
NO933558L (no) Benzimidazoler, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
ATE44961T1 (de) Substituierte o-sulfonyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
ZA871479B (en) Isohexide-nucleoside

Legal Events

Date Code Title Description
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE AG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 36 2O E 37 DA LPI NO 9.279 DE 14/05/1996.

B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: REFERENTE A RPI 1867 DE 17/10/2006.

B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 31.10.2018